Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Astragalus for Cognition in Alzheimer's Disease with Orthostatic Hypotension
NCT05647473Phase 2Recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Feb 2024
- Primary completion
- May 2025
- Modality
- Herbal supplement
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of astrgalus in Alzheimer's disease (AD) and orthostatic hypotension (OH) (3 arms), sponsored by Fujian Medical University Union Hospital. Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 48 weeks. Started Feb 2024; status: recruiting.
02
Drugs
astrgalus
03
Conditions
Alzheimer's disease (AD)orthostatic hypotension (OH)
Beyond the preview
Go deeper on NCT05647473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05647473.